In continuation of our work concerning the relation between the anticancer and anti-vascular endothelial growth factor receptor (anti-VEGFR-2) activity of some synthesized compounds, we hereby designed and prepared three new series of furochromone and benzofuran derivatives (carbonitriles, sulfonyl hydrazides and imides). The prepared compounds were evaluated for their in vitro VEGFR-2 inhibitory activity, their cytotoxicity on fifteen human cancer cell lines and their in vivo antiprostate cancer activity. The highest anti-VEGFR-2 activity was demonstrated by 6-acetyl-4-methoxy-7-methyl-5H-furo[3,2-g]chromen-5-one (3), which exhibited the same IC 50 value as the reference drug sorafenib (2.00 Â 10 À3 mM). On the other hand, most of the synthesized compounds showed potent cytotoxicity against most of the tested cell lines, in particular, the carbonitrile series (4a,b and 5a,d) which exhibited the best activity with IC 50 values ranging from 3.56 Â 10 À13 to 4.89 Â 10 À7 mM. Moreover, the imide series (15-17) showed the most significant in vivo antiprostate cancer activity. An in silico GOLD molecular docking study has been done to explore the binding mode of interaction of the furochromone and benzofuran derivatives to VEGFR-2 kinase, and to reveal the correlation between IC 50 (mM) of the enzymatic inhibition of VEGFR-2 kinase and the GoldScore fitness for further therapeutic application.
Introduction
Angiogenesis of tumor mass is the process of forming new blood vessels from the existing ones of a host, and is strictly controlled by the balance of a number of angiogenic factors. The imbalance is thought to affect angiogenesis, which is involved in the expansion and metastasis of solid tumors such as prostate, colon, breast, and gastric cancers. [2] [3] [4] [5] [6] The blockade of the tyrosine kinase VEGFR-2 (also known as Flk-1 for fetal liver kinase-1 or KDR for kinase insert domain-containing receptor) [7] [8] [9] signaling pathway may disrupt the angiogenesis process of a solid tumor so that the developing tumor cells grow slowly or even cease to grow. 10, 11 Antiangiogenic therapy is directed mainly at proliferating capillary endothelial cells and does not cause bone marrow suppression, gastrointestinal symptoms or hair loss.
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Some inhibitors of VEGFR-2 such as sunitinib 13 and sorafenib, 14 have been approved by the Food and Drug Administration for treating different kinds of tumors, also in literature chromone bioisosteres, 15, 16 benzofuran, 17, 18 carbonitrile, 19, 20 hydrazide, 21, 22 and imide derivatives, 23, 24 were identied as anti-VEGFR-2 and anticancer agents.
The previously mentioned studies encouraged us to design some furochromone and benzofuran derivatives in order to evaluate their biological activities and molecular docking.
Chemistry
The carbonitriles (4a-d and 5a-d), sulfonyl hydrazides (8a,b, 10a,b and 12a-c) and imides (15) (16) (17) were efficiently synthesized according to the protocols outlined in (Schemes 1-3). All the starting materials of the synthesized compounds were prepared according to the reported methods, while the general reaction conditions, procedures and compounds characterization of the newly synthesized derivatives were described in the experimental section.
Reuxing visnagin (1) in aqueous potassium hydroxide afforded the visnaginone derivative (2) , 25 which reacted with acetic anhydride in the presence of anhydrous sodium acetate under reux to give the acetyl visnagin derivative (3) . 26 The reaction of compound (3) with the respective aromatic aldehyde namely, (benzaldehyde, 4-bromobenzaldehyde, 5-methyl furfural and 3,4,5-trimethoxybenzaldehyde),in the presence of malononitrile and/or ethylcyanoacetate and ammonium acetate afforded the iminocarbonitrile (4a-d) and the oxocarbonitrile (5a-d) derivatives respectively.
Moreover, khellinone (7) and acetyl khellin (9) were prepared using the same previously mentioned method of preparation of visnaginone (2) and acetyl visnagin (3) respectively. The Mannich bases (11a-c) 27 were prepared by the reaction of visnaginone (2) with some secondary amines namely, (piperidine, N-methyl piperazine and morpholine) in ethanol in the presence of formaline. The different aryl sulfonyl hydrazides (8a,b, 10a,b and 12a-c) were synthesized by reacting the previously mentioned acetyl containing compounds (2, 3, 7, 9 and 11a-c) with p-toluene sulfonyl hydrazide in methanol and few drops of conc. HCL.
Furthermore, chlorosulphonation of visnagin (1) at 0 C affored visnagin sulfonyl chloride (13) , 28 which upon stirring at room temperature with hydrazine hydrate 98% in 20 mL absolute ethanol and few drops of triethylamine gave the visnagin sulfonyl hydrazide (14) , 28 nally, the imide derivatives (15-17) were obtained by reuxing (14) with the appropriate anhydrides namely, (phthalic, succinic and maleic anhydrides) in glacial acetic acid.
Results and discussion
(1) Biology (a) In vitro anti-VEGFR-2 screening. Studying the anti-VEGFR-2 activity of the tested compounds (Table 1) showed that 6-acetyl-4-methoxy-7-methyl-5H-furo[3,2-g]chromen-5-one (3) , was the most active compound and exhibited the same IC 50 value as the reference drug sorafenib (2.00 Â 10 À3 mM).
(b) In vitro cytotoxicity screening. The cytotoxicity of the tested compounds (3, 4a-d, 5a-d, 8a,b, 10a,b, 11a-c, 12a-c, 14-17) was determined on een different human cancer cell lines (Table 2a-d) .
Screening the cytotoxicity of the tested compounds on cervical carcinoma (KB), leukemia (K561), neuroblastoma (NB-1), liver carcinoma (HepG2) cell lines, showed that compound (4b) has a very remarkable activity, with IC 50 values ranging from (4 The previous screening of the bioactivity of the tested compounds on the presented panel of cell lines indicated that, the majority of the synthesized compounds were signicantly potent than the comparative reference drugs used. The carbonitrile series (4a,b and 5a,d) showed the best potency against all the cell lines compared to the reference drugs and to the rest of the newly synthesized furochromone and benzofuran derivatives.
(C) In vivo antiprostate cancer activity. The results of the in vivo antiprostate cancer activity (Table 3) proved that the most signicant ED 50 values were observed for the imide derivatives (15-17) displaying (ED 50 from 2.12 mM to 2.82 mM) which was better than the reference drug utamide (ED 50 ¼ 11.60 mM).
(2) Docking studies
The computational docking methods are intensively applied to screen a variety of compounds, looking for new hits with specic binding affinities or by investigating a range of structural manipulation for an existing compound. 29 The proteinligand docking program GOLD facilitates this approach for prediction of the binding mode of the compounds under investigation. GOLD is considered as one of the exible docking programs that were tested on large test sets to give a 68% success rates on the CCDC/Astex validation set of 305 complexes taken from the Protein Data Bank (PDB).
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In this article, we have implemented the GoldScore as a search algorithmic function for "drug-like" which was reported to give superior results than the Chemscore function as a scoring function for GOLD. 31 This GoldScore tness means the higher the values of tness (Table 4) is the better binding interaction into the binding site.
The tness score is the negative sum of the component energy terms, such as protein-ligand external hydrogen bond energy (S hb_ext ), protein-ligand external van der Waals energy (S vdw_ext ), protein-ligand intramolecular hydrogen bond energy (S hb_int ), and the ligand internal van der Waals energy (S vdw_int ), so that larger tness scores are better.
The implemented GoldScore algorithmic function was initially evaluated for its accuracy into VEGFR-2 kinase. As a function of RMSD (root mean square deviation) of the runs done by exible docking using GOLD 5.1, the docking poses were nearest to the experimental binding mode of the cocrystallized ligands of VEGFR-2. 32 Our docking results are matched with the reported requirements for successful scoring function, 33 being of RMSD # 2.0Å from the experimental one. In this study, the newly synthesized compounds were docked into the target crystal structure of human Protein tyrosine kinase of VEGFR-2 kinase domain (pdb code: 3EWH) in complex with a pyridyl-pyrimidine benzimidazole inhibitor (K111). Many compounds revealed good Gold tness score (Table 4) .
Almost all the docked compounds show the common hydrogen bond interactions (1-4) with D1046 (NH, C]O), K868 (NH), E885 (C]O), and R1027 (NH). Fitness of the best docked compounds takes place within RMSD of 2.39-6.27Å as cited in (Table 4) . Such binding mode was identically similar to the native co-crystallized ligand (K111) which binds with similar binding orientation involving similar amino acids used by docked compounds. This reveals that the interactions between the K868 (NH) and the small molecules will be crucial to inhibit the VEGFR-2 kinase activity.
Compound (4a) possess a high potential tness (GoldScore: 72) into the binding site of the 3D macromolecule (PDB: 3EWH). Its high affinity is presumably attributed to its hydrogen bond formed between its 5-C]O group and D1046 (NH) amino acid and RMSD of 4.44Å. In addition to the hydrophobic interaction of its 4 0 -phenyl pyridine moiety which occupies the hydrophobic pockets of the receptor site (I888, I889, I892, V898, V899, and I1044), as illustrated in Fig. 1 . Compound (4b) has a better potential tness (GoldScore: 74) into the binding site, forming one hydrogen bond between its terminal 4 00 -Br and R1027 (NH) amino acid. In addition, both compounds (4a and 4b) revealed external vdw of 52.43 and 53.55, respectively. As shown in (Fig. 2 ) and cited in (Table 4) , compound (12a) (GoldScore: 74.71) has a promising antiproliferative activity through its higher kinase binding affinity. Where it binds into VEGFR2 kinase through two hydrogen bonds between its 4-CH 3 O and 6-O moieties and K868 (HN), and D1046 (HN) amino acids, respectively, where it revealed excellent RMSD of 2.39Å. Furthermore its 7-piperidinyl moiety occupies the extended hydrophobic pocket similarly to the lipophilic triuoromethyl-arene portion of the native cocrystallized (K111).
In addition to the role of the hydrogen bond and vdw interactions, the hydrophobic interaction plays a signicant role to occupy the 3(4 0 -aryl pyridine) moiety of compounds (4a-d and 5a-d), and the 7-piperidinyl, N-Me piprazinyl, and morpholino moieties of compounds (11a-c and 12a-c) into the extended hydrophobic pocket similarly to the lipophilic triuoromethyl-arene portion of the native co-crystallized (K111).
In the analysis of GOLD docking results, a high correlation (R 2 ¼ 0.712) between IC 50 of (VEGFR-2) enzymatic inhibition and the GoldScore tness for compounds (4b,c, 5a-c, 8a, 10a,b, 11c, 12a, 16 and 17) into (VEGFR-2) kinase is shown in (Fig. 3A) . 
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Conclusion
The previously mentioned discussions indicated that the more lipophilic agents may be antiangiogenic rather than cytotoxic agents, and suggested that VEGFR-2 kinase inhibition may not be critical for the cytotoxic responses of our compounds. For example, the phenyl (5a) and trimethoxy phenyl (5d) derivatives have a potent cytotoxic effects against different tumor cells such as HL60, U937, K561, G361, SK-MEL-28, PC-3, HT1080, HepG2, KB, SK OV-3, SF-268, NCI H460, and RKOP27 in IC 50 of 10 À6 to 10 À13 mM range. Whereas, their 4-bromophenyl derivative (5b) being more lipophilic inhibited these tumor cells in much lower IC 50 of 10 À3 to 10 À5 mM range, despite its higher VEGFR-2 inhibition (IC 50 of 2.20 Â 10 À3 mM). The VEGFR-2 inhibition of compound (5b) is almost of the same potency of the reference drug sorafenib being of (IC 50 of 2.00 Â 10 À3 mM).
On the other hand, the in vivo results of these compounds are correlated with this outcome, where compound (5b) revealed better in vivo antiprostate cancer activity (ED 50 ¼ 13.11 mM) than that of compounds (5a and 5d) (ED 50 ¼ 26.00 and 28.60 mM, respectively). This suggests that their prostate cancer antiproliferative activities are mediated through VEGFR-2 pathway.
Likewise within the in vivo prostate cancer experiment, compounds (15) (16) (17) 
Experimental
(1) Chemistry
Melting points were determined on Electrothermal IA 9000 apparatus and were uncorrected. The infrared (IR) spectra were recorded using Nexus 670 FT-IR FT-Raman spectrometer as potassium bromide discs, at National Research Centre. The proton nuclear resonance ( 1 H NMR) spectra were determined on Varian mercury 500 MHz spectrometer, using tetramethylsilane (TMS) as the internal standard, at National Research Centre. The mass spectra were performed on JEOL JMS-AX500 mass spectrometer at the National Research Centre. The reactions were followed by thin layer chromatography (TLC) (Silica gel, aluminum sheets 60 F254, Merck) using benzene: ethyl acetate (8 : 2 v/v) as eluent and sprayed with iodine-potassium iodide reagent. The purity of the newly synthesized compounds was assessed by elemental analysis and was found to be higher than 95%. Preparation of 1-(6-hydroxy-4-methoxybenzofuran-5-yl)ethanone (2), 6-acetyl-4-methoxy-7-methyl-5H-furo[3,2-g]chromen-5-one (3). Visnaginone (2) 25 and acetyl visnagin (3) 26 were prepared according to the reported methods.
General procedure for the preparation of different iminocarbonitriles (4a-d). Acetyl visnagin (2.5 mmol) together with the respective aromatic aldehyde (2.5 mmol) namely, (benzaldehyde, 4-bromobenzaldehyde, 5-methyl furfural and 3,4,5-trimethoxybenzaldehyde), malononitrile (2.5 mmol) and ammonium acetate (20 mmol) were reuxed for 10-14 hours in ethanol (30 mL). The precipitate formed was ltered, washed with ethanol, dried and crystallized from DMF-ethanol (1 : 10).
2-Amino-6-(4-methoxy-7-methyl-5-oxo-5H-furo[3,2-g]chromen-6-yl)-4-phenylpyridine-3-carbonitrile (4a 2-Amino-6-(4-methoxy-7-methyl-5-oxo-5H-furo[3,2-g]chromen-6-yl)-4-(5-methylfuran-2-yl)pyridine-3-carbonitrile (4c a Root mean square deviation.
General procedure for the preparation of different oxocarbonitriles (5a-d). Acetyl visnagin (2.5 mmol) together with the respective aromatic aldehyde (2.5 mmol) namely (benzaldehyde, 4-bromobenzaldehyde, 5-methyl furfural and 3,4,5-trimethoxybenzaldehyde), ethylcyanoacetate (2.5 mmol) and ammonium acetate (20 mmol) were reuxed for 10-14 hours in ethanol (30 mL). The precipitate formed was ltered, washed with ethanol, dried and crystallized from DMF-ethanol (1 : 10).
1,2-Dihydro-6-(4-methoxy-7-methyl-5-oxo-5H-furo[3,2-g]chromen-6-yl)-2-oxo-4-phenylpyridine-3-carbonitrile (5a Preparation of 1-(6-hydroxy-4,7-dimethoxybenzofuran-5-yl)ethanone (7), 6-acetyl-4,9-dimethoxy-7-methyl-5H-furo[3,2-g]chromen-5-one (9), 1-(6-hydroxy-4-methoxy-7-(piperidin-1-ylmethyl)benzofuran-5-yl)ethanone (11a), 1-(6-hydroxy-4-methoxy-7-((4-methylpiperazin-1-yl)methyl)benzofuran-5-yl)ethanone (11b), 1-(6-hydroxy-4-methoxy-7-(morpholinomethyl)benzofuran-5-yl) ethanone (11c). Khellinone (7), 25 acetyl khellin (9) 26 and the Mannich bases (11a-c) 27 were prepared according to the reported methods. Fig. 1 The docking fitness of compounds 4a (cyan sticks) and 4b (balls and sticks) involving flexible GOLD docking into VEGFR-2 kinase. They exhibited one hydrogen bond for each, shown as green dashed lines with D1046 and R1027, respectively. Protein is shown as solid backbone ribbon and the binding site is shown in solid surface view with labeled amino acids. Fig. 2 The binding affinity of compounds 12a (balls and sticks) into the binding site of VEGFR-2 kinase within RMSD of 2.39Å. It reveals GoldScore fitness of 74.71 and two hydrogen bonds (green dotted lines) with NH group of K868 and D1046. Its piperidine moiety is located between its two hydrophobic pockets similarly to the CF 3 group of the native ligand.
General procedure for the preparation of different aryl sulfonylhydrazides (8a,b, 10a,b, 12a-c) . To the appropriate ketone (2, 3, 7, 9 and 11a-c) (0.02 mol),dissolved in methanol (15 mL), p-toluene sulfonyl hydrazide (0.025) dissolved in methanol (30 mL) was added, then 2-3 drops of conc. HCL were added to the reaction mixture. The reaction mixture was kept at room temperature overnight, where crystals of the product were separated out, ltered, dried and then crystallized from methanol.
5-(1-Tosylhydrazono-ethyl)-4-methoxy-benzofuran-6-ol (8a Preparation of 4-methoxy-7-methyl-5-oxo-5H-furo[3,2-g] chromene-9-sulfonylchlo-ride (13) and 4-methoxy-7-methyl-5-oxo-5H-furo[3,2-g]chromene-9-sulfonylhydr-azide (14) . Visnagin sulfonyl chloride (13) 28 and Visnagin sulfonyl hydrazide (14)
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were prepared according to the reported methods.
General procedure for the preparation of different imino derivatives (15) (16) (17) . To a solution of visnagin-4-sulphonyl hydrazide (0.01 mol) in glacial acetic acid, the appropriate anhydrides namely, (phthalic anhydride, succinic anhydride and maleic anhydride) (0.005 mol) were added. The mixture was reuxed for 6-8 hours, poured onto ice cold water, the formed precipitate was ltered, washed with water and crystallized from glacial acetic acid to give the product.
4-Methoxy-7-methyl-5-oxo-5H-furo[3,2-g]chromene-9-sulfonic acid(1,3-dioxo-1,3-dihydro-isoindol-2-yl)amide (15 (2) Biology VEGFR-2 kinase activity assays by ELISA. 34 The assay was performed in 96-well plates pre-coated with 20 mg mL À1 poly (Glu, Tyr) 4 : 1 using sorafenib and DMSO as positive and negative controls respectively, experiments at varying concentrations (1 nM to 1 mM) were performed in triplicate, where 85 mL of an 8 mM ATP solution and 10 mL of the compound were added in each well. The reaction was initiated by adding VEGFR-2 kinase (5 mL), followed by addition of 100 mL of anti-phosphotyrosine antibody (PY99; 1 : 500 dilution) then goat anti-mouse IgG horseradish peroxidase (100 mL; 1 : 2000 dilution) diluted in T-PBS containing 5 mg mL À1 BSA was added. Aer each addition there was an incubation period of 1 h at room temperature followed by washing. Finally, 100 mL of (0.03% H 2 O 2 , 2 mg mL À1 o-phenylenediamine in citrate buffer 0.1 M, pH 5.5) was added and incubated at room temperature until color developed. The reaction was terminated by the addition of 100 mL of 2 M H 2 SO 4 . The inhibition rate (%) was calculated using the following equation:
, where, A 492 was measured using a multiwell spectrophotometer (VERSAmax™).
In vitro cytotoxicity screening. 35 Cells were plated in 96-multiwell plate (5000 to 40 000 cells per well) for 24 h before treatment with the compounds to allow attachment of cell to the wall of plate, a solution of each tested compound was prepared by solubilizing each in DMSO 400-fold the desired nal maximum test concentration.
Aer being incubated for 24 h, cells were treated with different concentrations of each compound under test, where an aliquot of frozen concentrate was diluted to twice the desired nal maximum test concentration and four 10 fold serial dilutions were made to provide a total of ve drug concentrations plus control. The cells were incubated with the compounds for 48 h at 37 C and in atmosphere of 5% CO 2 . Control cells were treated with vehicle alone. Aer 48 h, cells were xed, washed and stained with sulforhodamine B (SRB) (0.4% w/v) dissolved in 1% acetic acid for 10 min. Excess stain was washed with acetic acid and attached stain was solubilized with 10 mM trizma base. The absorbance was measured in an automated plate reader at wave length of 515 nm. The concentration required for 50% inhibition of cell viability (IC 50 ) was calculated and compared with the reference drugs.
In vivo evaluation of antiprostate cancer activitiy. 36 Testosterone propionate (TP, 0.5 mg kg À1 ) dissolved in cotton seed oil containing 5% ethanol was administered to castrated male Wistar rats treated with androgen, three days aer castration, once daily for 5 days alone or in combination with the tested compounds (10-30 mg kg À1 ) suspended with 0.5% methylcellulose. The rats were sacriced aer nal dosing, and both ventral prostates and seminal vesicles-coagulate glands were removed and weighed. The antiprostate cancer activity was expressed as a percentage of inhibition of the TP effect.
(3) Molecular docking
GOLD soware package, version 5.1 (Cambridge Crystallographic Data Centre, Cambridge, U.K.), 37 was used, the receptors were prepared using Hermes visualizer in the GOLD Suite, and the region of interest was selected as all the protein residues within the 10Å of the reference ligands.
For pose selection and enrichment studies default values of speed settings and all other parameters were used. GOLD Score tness algorithmic function was used with a default input and annealing parameters, which were managed within 4.0 and 2.5 A for the van der Waals and H-bond interactions, respectively 38, 39 All the docked ligands were energetically minimized by using MOPAC with 100 iterations and minimum RMS gradient of 0.10.
In this study, 10 genetic algorithm (GA) docking runs were used with internal energy offset. For pose reproduction analysis, the radius of the binding pocket was set as the maximal atomic distance from the geometrical center of the ligand plus 3Å. When the top three solutions attained RMSD values within 1.5Å, docking was terminated.
The top ranked docking pose was retained for the 3D cumulative success rate analysis. Rescoring was conducted with the GOLD rescore option, in which poses would be optimized by the program. The top 10 ranked docking poses were selected based on their Gold tness scores and their reported mode of interactions, which were analyzed using Accelrys Discovery studio to reveal the hydrogen bond interaction and binding mode within the binding domain.
With respect to ligand exibility, ipping of all planar RNR1R2 ring, NH-R ring, carboxylic acids -COOH were included, and the torsion angle distribution and post process rotatable bonds were set as default. All other Genetic Algorithm parameters were set as default settings.
The crystal structure of the (VEGFR-2) kinase domain in complex with N-[4-({3-[2-(methylamino)pyrimidin-4-yl]pyridin-2-yl}oxy)naphthen-1-yl]-6-(triuorometh-yl)-1H-benzimidazol-2-amine (K111) co-crystalized ligand (pdb code: 3EWH) was used as target protein structure, which was retrieved from the Protein Data Bank (PDB). PDB sum was accessed for identication of the key amino acids and the exible residues (E885, T916, and D1046) in the binding site. All residues within 10Å radius from the origin: 13.237, À2.016 and 11.23 of the co-crystallized ligand coordinates.
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